Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica · 2025
Discovering a new nutraceutical based on pollen extract and teupolioside: a prospective monocentric study evaluating its role in alleviating lower urinary tract symptoms in benign prostatic hyperplasia patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lo Re Mattia, Pezzoli Marta, Cadenar Anna, Fuligni Elettra, Gajo Leonardo, Minervini Andrea, Cocci Andrea
Аннотация
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common condition in men over 50, leading to lower urinary tract symptoms (LUTS). A nutraceutical containing pollen extract (Graminex® G96®) and teupolioside has shown potential in alleviating LUTS by targeting inflammation and dihydrotestosterone production. This prospective, monocentric study enrolled 60 patients with mild to moderate LUTS due to BPH.
METHODS: Participants received one tablet daily for three months. Assessments included the international prostate symptom score (IPSS), quality of life (QoL), uroflowmetry, postvoid residual (PVR), and sexual function (IIEF-5, MSHQ EjD).
RESULTS: Fifty-three patients completed the follow-up. Significant improvements were observed in IPSS and QoL (p<0.001), with scores decreasing from 14 (11-16) at baseline to 10 (8-12) at three months and decreasing from 3 (2-3) to 2 (2-2), respectively. Uroflowmetry parameters (Qmax and PVR) improved, increasing from 12 (11-16) ml/s to 15 (11-17) ml/s and decreasing from 50 (30-55) ml to 35 (25-45) ml, respectively, without statistical significance (p>0.05). Sexual function and PSA levels remained stable, with no significant adverse effects reported.
CONCLUSIONS: The combination of pollen extract and teupolioside effectively alleviates LUTS in BPH patients with a favorable safety profile, particularly in avoiding sexual dysfunction.
METHODS: Participants received one tablet daily for three months. Assessments included the international prostate symptom score (IPSS), quality of life (QoL), uroflowmetry, postvoid residual (PVR), and sexual function (IIEF-5, MSHQ EjD).
RESULTS: Fifty-three patients completed the follow-up. Significant improvements were observed in IPSS and QoL (p<0.001), with scores decreasing from 14 (11-16) at baseline to 10 (8-12) at three months and decreasing from 3 (2-3) to 2 (2-2), respectively. Uroflowmetry parameters (Qmax and PVR) improved, increasing from 12 (11-16) ml/s to 15 (11-17) ml/s and decreasing from 50 (30-55) ml to 35 (25-45) ml, respectively, without statistical significance (p>0.05). Sexual function and PSA levels remained stable, with no significant adverse effects reported.
CONCLUSIONS: The combination of pollen extract and teupolioside effectively alleviates LUTS in BPH patients with a favorable safety profile, particularly in avoiding sexual dysfunction.